Chong Kun Dang Pharmaceutical (185750) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩21.45 Billion ≈ $14.54 Million USD) by net assets (₩945.54 Billion ≈ $640.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chong Kun Dang Pharmaceutical - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Chong Kun Dang Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Chong Kun Dang Pharmaceutical balance sheet liabilities for a breakdown of total debt and financial obligations.
Chong Kun Dang Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chong Kun Dang Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anshan Senyuan Road Bridge
SHE:300210
|
0.026x |
|
Guangdong Chant Group Inc
SHE:002616
|
0.235x |
|
Era Co Ltd
SHE:002641
|
0.002x |
|
Cementos Pacasmayo S.A.A
F:EPCC
|
0.123x |
|
Shaanxi Construction Machinery Co Ltd
SHG:600984
|
0.029x |
|
Renta 4 Banco S.A
MC:R4
|
0.031x |
|
Sonata Software Limited
NSE:SONATSOFTW
|
0.021x |
|
Guangdong Senssun Weighing Apparatus Group Ltd
SHE:002870
|
0.048x |
Annual Cash Flow Conversion Efficiency for Chong Kun Dang Pharmaceutical (2016–2024)
The table below shows the annual cash flow conversion efficiency of Chong Kun Dang Pharmaceutical from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Chong Kun Dang Pharmaceutical market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩896.38 Billion ≈ $607.46 Million |
₩64.29 Billion ≈ $43.57 Million |
0.072x | -81.61% |
| 2023-12-31 | ₩815.64 Billion ≈ $552.74 Million |
₩318.16 Billion ≈ $215.61 Million |
0.390x | +257.79% |
| 2022-12-31 | ₩621.29 Billion ≈ $421.04 Million |
₩67.73 Billion ≈ $45.90 Million |
0.109x | +378.04% |
| 2021-12-31 | ₩565.81 Billion ≈ $383.44 Million |
₩12.90 Billion ≈ $8.74 Million |
0.023x | -87.94% |
| 2020-12-31 | ₩551.59 Billion ≈ $373.81 Million |
₩104.32 Billion ≈ $70.70 Million |
0.189x | +16.22% |
| 2019-12-31 | ₩474.95 Billion ≈ $321.87 Million |
₩77.29 Billion ≈ $52.38 Million |
0.163x | +64.50% |
| 2018-12-31 | ₩430.90 Billion ≈ $292.01 Million |
₩42.63 Billion ≈ $28.89 Million |
0.099x | -51.15% |
| 2017-12-31 | ₩403.29 Billion ≈ $273.31 Million |
₩81.67 Billion ≈ $55.35 Million |
0.203x | +24.15% |
| 2016-12-31 | ₩354.25 Billion ≈ $240.07 Million |
₩57.79 Billion ≈ $39.16 Million |
0.163x | -- |
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. The company provides prescription drugs for anti-hypertension, anti-hyperlipidemia, anti-diabetics, and immunosuppressants; over-the-counter medicine comprising headache remedies, dewormers, digestive aids, and vitamins; probiotics and Omega-3 supplements; and he… Read more